Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 13/20 | 0.49 |
| ▸ | ABL2 | P42684 | 6/20 | 0.49 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614720 | 1.00 | MAPK14 (0.50) | MAPK14KDREGFRLCKCSF1R | |
| SCHEMBL29614711 | 0.89 | ABL1 (0.63) | MAPK14KDRABL1ABL2SRC | |
| SCHEMBL19307185 | 0.89 | ABL1 (0.63) | MAPK14KDRABL1ABL2SRC | |
| SCHEMBL29614737 | 0.88 | MAPK14 (0.59) | MAPK14KDREGFRLCKCSF1R | |
| SCHEMBL19307214 | 0.88 | MAPK14 (0.59) | MAPK14KDREGFRLCKCSF1R | |
| SCHEMBL29614747 | 0.84 | RET (0.58) | MAPK14KDREGFRLCKCSF1R | |
| SCHEMBL19307088 | 0.84 | RET (0.58) | MAPK14KDREGFRLCKCSF1R | |
| SCHEMBL19307100 | 0.83 | ABL1 (0.56) | MAPK14KDRABL1ABL2SRC | |
| SCHEMBL29614892 | 0.83 | ABL1 (0.56) | MAPK14KDRABL1ABL2SRC | |
| SCHEMBL19307122 | 0.83 | ABL1 (0.55) | MAPK14KDRABL1ABL2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | MAPK14 1309/4885KDR 4774/4885EGFR 3627/4885 |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | MAPK14 1389/4885KDR 4666/4885EGFR 3463/4885 |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | MAPK14 1309/4885KDR 4774/4885EGFR 3627/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | MAPK14 4190/4885KDR 4418/4885EGFR 4828/4885 |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | MAPK14 1389/4885KDR 4666/4885EGFR 3463/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | MAPK14 1309/4885KDR 4774/4885EGFR 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.